verywellhealth · 3d
Novo Nordisk's Experimental Oral Drug Reports 'Remarkable' Weight Loss, Early Data Shows
In a phase 1 trial, Novo Nordisk's experimental obesity drug amycretin led to up to 13% weight loss in just three months. Amycretin targets GLP-1 receptors and a second hormone called amylin. Amylin appears to act in the brain,
In Depth
Benzinga.com · 1d
EXCLUSIVE: Novo Nordisk Faces Political Heat Over Weight-Loss Drug Prices Ahead Of Elections, Yet 'The Real Issue Is With The Middlemen'
Novo Nordisk under political pressure over high U.S. drug prices as CEO testifies before Congress. PBMs and limited impact on company's bottom line.
YAHOO!News · 5d
Novo Nordisk's New Weight Loss Drug Shows Ominous Psychiatric Side Effects
Novo Nordisk, tje manufacturer behind Ozempic and Wegovy has another weight loss medication in the works — but according to its trial results, it has some pretty freaky side effects. As Fierce Biotech reports,
FiercePharma · 20h
Novo Nordisk scolded by UK drug marketing watchdog over sponsorship of weight loss services
Novo Nordisk has earnt yet another dressing down from the PMCPA. The U.K. | Novo Nordisk has earnt yet another dressing down from the PMCPA. The U.K. self-regulatory body found fault with Novo’s support for U.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results